When facing the devastating reality of recurrent cancer, particularly for high-risk individuals, the imperative for innovative therapeutic solutions to improve survival rates becomes critically clear. This urgency is profoundly evident in the realm of pediatric neuroblastoma, an exceptionally aggressive and often lethal form of childhood cancer. Disturbingly, it stands as the primary cause of cancer-related fatalities in children aged one to five years, underscoring the desperate need for advanced interventions. From a strategic perspective, the grim statistics associated with neuroblastoma highlight a significant unmet need in global healthcare, driving specialized centers to become vital healthcare destinations for families worldwide.

Neuroblastoma typically originates in the early nerve cells of children. A significant challenge lies in its common presentation: by the time a diagnosis is made, the cancer has frequently metastasized to other bodily regions, rendering its management particularly arduous. In our view, this widespread dissemination at diagnosis complicates traditional treatment paradigms and necessitates a focus on systemic, targeted approaches, which is where innovative clinical trials truly shine.

Currently, the most formidable obstacle confronting clinicians in the management of neuroblastoma patients is the development of effective strategies to avert disease relapse. Dr. Giselle Sholler, a distinguished pediatric oncologist and the director of the Isabella Santos Foundation Solid and Rare Tumor Program at Atrium Health Levine Children’s, who also chairs the Beat Childhood Cancer Research Consortium, articulated this challenge: “We can get kids into remission with very aggressive chemotherapy and intensive therapy. When we stop therapy, however, 40-50% of children relapse.” This stark reality underscores the critical importance of post-remission strategies in international patient care and the quest for enduring quality of care.

Pioneering Therapies: Targeting Neuroblastoma Stem Cells

Dr. Sholler and her dedicated team are at the forefront of an FDA-sponsored clinical trial, operating under the umbrella of the Beat Childhood Cancer (BCC) Research Consortium. This consortium represents a formidable alliance of over 40 universities and children’s hospitals, collectively forming a worldwide network dedicated to childhood cancer clinical trials. The trial’s innovative design specifically targets the cancer stem cell pathway, aiming to prevent neuroblastoma recurrence in young patients. This two-year study is evaluating difluoromethylornithine (DFMO), an antiparasitic medication initially developed to combat African sleeping sickness. In the context of neuroblastoma, DFMO functions by inhibiting a specific gene crucial for cancer development, thereby arresting the proliferation of cancer cells. This strategic focus on cancer stem cells represents a paradigm shift, moving beyond simply reducing tumor bulk to eradicating the root cause of relapse, a critical advancement for patients seeking cross-border healthcare.

Breakthrough Results and FDA Recognition

The preliminary outcomes of this groundbreaking research have been exceptionally promising. Dr. Sholler shared the encouraging findings: “Through our study of DFMO, we have shown that we can keep more kids in remission, with only about 15% of them relapsing.” She further added, “We’re very excited to report that we have 97% of patients still alive 4 years after treatment instead of just 80% of patients.” These statistics represent a significant leap forward in pediatric oncology, offering renewed hope to families engaged in patient travel for specialized treatment. Recognizing its potential, Levine Children’s and the BCC Research Consortium were granted breakthrough therapy designation by the FDA for DFMO in April of 2020. The DFMO trial itself encompasses more than 40 hospitals across both the U.S. and Canada, signifying a broad collaborative effort in advancing global healthcare.

Global Reach: Facilitating International Patient Access

In a commendable effort to extend the benefits of this revolutionary therapy to as many children as possible, Levine Children’s has proactively made the DFMO trial accessible to patients across the globe. Indeed, the trial’s enrollment proudly includes dozens of international patients. This commitment solidifies Levine Children’s reputation as a leading healthcare destination for complex pediatric conditions, attracting families engaged in medical tourism from diverse corners of the world.

A Holistic Approach to Cross-Border Healthcare

For families embarking on patient travel to Levine Children’s for DFMO treatment, the institution provides comprehensive Global Healthcare Services. These services are meticulously designed to support families through every step of their journey. Dr. Sholler elaborated on the vital role of this specialized team: “Our Global Healthcare Services team makes it easy for patients to get world-class care by coordinating medical care, appointments, travel logistics, language services and all other arrangements.” She further expressed her admiration, stating, “I’ve been amazed by how this team has embraced families from different communities and cultures, allowing them to maintain their focus on their child during their visit.” From a management consulting perspective, these integrated services are not merely conveniences; they are critical enablers of successful cross-border healthcare, significantly reducing the logistical and emotional burden on families and enhancing the overall international patient care experience. This level of support is a hallmark of a premier health tourism provider.

We are privileged to share the poignant narratives of Thanos and Helena, two international patients whose families undertook significant journeys to seek advanced neuroblastoma treatment at Levine Children’s, drawn by Dr. Sholler’s distinguished reputation for clinical excellence and cutting-edge care.

Journeys of Hope: International Patients Seeking Life-Saving Care

Athanasios (Thanos) Tararas: A Greek Family’s Quest for Treatment

Age: 2 | Location: Greece

Christina Vouli, Thanos’s mother, recounted her son’s medical odyssey: “Thanos first started showing signs of cancer on March 9, 2020, when he developed a high fever and low blood counts. On March 13, we got the neuroblastoma diagnosis from our local hospital in northern Greece. His treatment started with surgery on April 2, 2020. Then, he started chemo on April 16.” The family’s proactive approach to patient travel began with extensive personal research into neuroblastoma treatments and available trials, which led them to Dr. Sholler’s published articles. They also connected with other parents who were part of the DFMO trial. Their initial consultation with Dr. Sholler at Levine Children’s occurred on July 6, 2021.

Christina expressed profound satisfaction with their experience: “Working with Dr. Sholler and her team has been amazing. The cooperation between our Greek physician team and Dr. Sholler’s team has given us a feeling of security, knowing that our child receives the best possible treatment.” Thanos’s current regimen involves a low-dose DFMO treatment, administered as four pills daily, which is slated to continue until July 2023. His mother shared their relief that he is undergoing this treatment without experiencing any adverse side effects. “Our family is trying to return to normal life now that his condition is much more manageable,” she concluded, highlighting the transformative impact of accessing specialized quality of care through medical tourism.

Helena Mantovani: A Brazilian Physician’s Pursuit of a Cure

Age: 6 | Location: Brazil

Juliana Mantovani Bottós, Helena’s mother, an ophthalmologist by profession, shared her daughter’s challenging medical journey: “Our family is from Brusque, Santa Catarina, which is located in southern Brazil. We first noticed a change in Helena, our only child, in June 2019. She had started complaining of pain in her hip and left leg, and she was beginning to limp.” Helena initially underwent the standard neuroblastoma protocol in Brazil. However, a significant hurdle emerged: “Unfortunately, the immunotherapy, a very important tool for survival, was not approved in our country. Plus, Helena was resistant to chemotherapy.” This critical lack of advanced treatment options propelled the family into patient travel for cross-border healthcare. “So we left everything behind and moved to Spain, trying to save our little warrior. We lived in Spain for 2 years. After finishing the standard treatment, we returned to Brazil.”

Juliana’s professional background as a physician proved invaluable. “I’m an ophthalmologist. But when I found out about Helena’s cancer, I immediately stopped working in my medical specialty, and I started to study all about neuroblastoma.” During her intensive research, she discovered studies on novel therapies aimed at reducing the risk of relapse. Following nearly two years of rigorous treatment, encompassing high-dose chemotherapy, chemoimmunotherapy, stem cell transplant, radiotherapy, and maintenance immunotherapy, the Mantovani Bottós family approached their oncology team to explore Helena’s potential participation in the DFMO clinical trial with Dr. Sholler.

After a few months, they journeyed to Charlotte, where they were warmly received by Dr. Sholler and her team at Levine Children’s. Juliana recounted their experience: “All the concern, attention and affection we received made us feel really special.” She emphasized the profound significance of the DFMO trial, which promises to reduce the relapse rate to 15%. “Of course, our worst nightmare is a relapse. But having Dr. Sholler’s wonderful team working to eliminate neuroblastoma and improve survivorship in children is a gift to all humanity.” Helena is currently taking DFMO orally twice daily for two years, experiencing minimal side effects. Her treatment plan requires monthly evaluations at her home hospital, supplemented by regular patient travel to Levine Children’s every three to six months during the two-year course of treatment. “We are very happy about this incredible opportunity to save our child’s life. Seeing our little girl return to her life, including her school, friends and family, is the best gift anyone could give us.” As a physician, Juliana deeply appreciates the effort involved: “As a physician, I know how much work goes into a clinical trial, and I’m aware of all the professional and personal dedication required to reach its goal. But I also imagine how gratifying it is to know that your life has made a huge difference in the lives of many children and their families. We are very grateful to each one involved in this incredible work.” Helena’s story powerfully illustrates the lengths families will go for quality of care and the profound impact of successful international patient care.

Managing Treatment: Dosage, Side Effects, and Eligibility

During the DFMO treatment, the majority of patients typically ingest two to three pills twice daily. Dr. Sholler highlighted the favorable side effect profile: “About 70% of kids in our first clinical trial had no side effects. Most of our kids are able to live a normal life at home and at school, with few side effects from treatment.” This minimal disruption to daily life is a crucial factor for families considering medical tourism, as it allows for a better quality of life during treatment, aligning with aspects of wellness tourism even within a critical medical context.

While most children tolerate DFMO well, a small cohort of patients may experience temporary hair thinning, dry skin, or reversible hearing loss. Dr. Sholler and her clinical team possess the expertise to adjust dosages as needed, effectively managing these potential side effects. The DFMO trial is specifically designed for any child diagnosed with high-risk neuroblastoma who has already completed the standard course of treatment. To be eligible, children must demonstrate minimal disease status or be in remission. For younger patients who have experienced a relapse or are still contending with active disease, Levine Children’s offers several other DFMO trials, including combinations with oral chemotherapy for those with ongoing disease, ensuring a comprehensive approach to international patient care.

The Future of Pediatric Cancer Treatment: A Vision for Global Access

Reflecting on the progress made, Dr. Sholler shared her long-term vision: “When I started taking care of kids with neuroblastoma, there was only a 30% chance of survival. As a researcher and physician, I wanted to make real a difference and change outcomes.” She emphasized the significant strides achieved: “We’ve made a huge jump in improving outcomes with this trial. Our goal, as we work with the FDA towards approval, is to make this treatment available to children in every rural community – not just the ones who can travel.” This aspirational goal speaks to the broader ethical imperative of ensuring equitable access to life-saving therapies, transcending geographical and socioeconomic barriers. It suggests a future where the benefits of medical tourism are not just for the few, but where advanced treatments become globally accessible, transforming global healthcare for pediatric oncology.

Bottom Line: Advancing Global Pediatric Oncology

The groundbreaking DFMO trial at Levine Children’s, in collaboration with the Beat Childhood Cancer Research Consortium, represents a monumental stride in the fight against high-risk neuroblastoma. The success of this initiative underscores several critical takeaways for the global healthcare community and families navigating complex medical decisions:

  1. Innovative Treatment Pathways: Targeting cancer stem cells with agents like DFMO offers a promising new approach to preventing relapse, moving beyond conventional chemotherapy to more precise, effective interventions.
  2. Collaborative Research Power: The Beat Childhood Cancer Research Consortium exemplifies the profound impact of multi-institutional collaboration in accelerating clinical trials and expanding access to cutting-edge therapies for international patients.
  3. Critical Role of Specialized Healthcare Destinations: Institutions like Levine Children’s serve as vital healthcare destinations, attracting families globally due to their commitment to pioneering research and superior quality of care.
  4. Enabling International Patient Care: Comprehensive Global Healthcare Services are indispensable for facilitating patient travel and ensuring a seamless, supportive experience for families undertaking cross-border healthcare journeys.
  5. A Vision for Equitable Access: The ultimate goal extends beyond clinical success to ensuring that these life-saving treatments become accessible to all children, regardless of their location, thus shaping the future of medical tourism into one of universal access.

The news signal for this article was referred from: https://news.google.com/rss/articles/CBMivAFBVV95cUxOY0VGU3RYMFltczNmdDVHN29LZW5HbzYzUzRUZDc4bDJQaUJxTTVsblQ2MlVmLVJ0aUlRbW00S3REaXprOFh1bkVCQ3FkeVVhLXotbTJJSWhXQmhGTEhEOV9GNkxYb0tFTElycllRVjdwYXluSkNMMWplaFl5cGVZMkNXYzlYRFVCTkhBWmNJN3BqcGNycEE3QlUydzFGWUIzRjZTNURmWmZrUEFHMDRMU2NjakJGX3JYdG52LQ?oc=5